Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma

Currently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially with BRAF wild-type. However, several checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Jan-Michael, Schweinsberg, Viola, Schroeter, Michael, von Reutern, Boris, Malter, Michael P., Schlaak, Max, Fink, Gereon R., Mauch, Cornelia, Galldiks, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384415/
https://www.ncbi.nlm.nih.gov/pubmed/30828569
http://dx.doi.org/10.3389/fonc.2019.00084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384415/
https://www.ncbi.nlm.nih.gov/pubmed/30828569
http://dx.doi.org/10.3389/fonc.2019.00084

Ejemplares similares